

JACKSON T. WRIGHT, JR., M.D., PH.D., F.A.C.P.
Term: 2005

Jackson T. Wright, Jr., M.D., Ph.D., F.A.C.P. is a Professor of Medicine, Division of Hypertension at Case Western Reserve University (CWRU), Program Director of the CWRU General Clinical Research Center, Director of the Clinical Hypertension Program at CWRU/University Hospitals of Cleveland and Acting Chief for the Division of Hypertension. In addition, he is Chief of the Hypertension Section at the Louis Stokes Cleveland V.A. Medical Center.

Dr. Wright grew up in Pittsburgh, Pennsylvania, received his B.A. from Ohio Wesleyan University and both his M.D. and Ph.D. (Pharmacology) from the University of Pittsburgh, School of Medicine (the first Black to do so). His housestaff training in Internal medicine was performed at the University of Michigan. In addition to being board certified in Internal Medicine, he was one of the first in the country to receive subspecialty board certification in Clinical Pharmacology. Prior to moving to CWRU in 1990, he served on the faculty in Clinical Pharmacology for 10 years at the Medical College of Virginia.

An experienced clinical investigator, Dr. Wright's primary research interest is in the clinical pharmacology of antihypertensive and cholesterol lowering agents, especially in minority populations. Among his many professional affiliations, he is fellow of the American College of Physicians, the Council for High Blood Pressure Research of the American Heart Association, and the Association of Black Cardiologists.

He has published extensively (over 130 articles, book chapters, and abstracts) and served on many national and internal advisory panels. Among these, he currently serves on the National High Blood Education Program Coordinating Committee, the NIH advisory panel responsible for coordinating high blood pressure control efforts in the United States. He also serves on the Advisory Committee for the NIH Office of Research on Women's Health. His NIH research experience includes service as Vice Chair of the Steering Committee for the NIH-sponsored AASK Trial, on which he also chaired the Design Subcommittee, and is Principal Investigator for the CWRU Clinical Center. This trial in 1,100 patients is currently evaluating the best treatment to prevent the most common cause of kidney failure in the Black community. In addition, he was selected to Chair the Executive Committee and serve as Vice Chair of the Steering Committee for the largest study of the treatment of high blood pressure and cholesterol ever conducted, the ALLHAT study. This NIH-sponsored 7-year trial has recruited 42,448 participants, including over 15,100 African Americans at 623 sites in the US, Canada, the Virgin Islands, and Puerto Rico. Recently, he was selected to serve as PI of one of seven clinical centers to participate in the NIDDK sponsored Chronic Renal Insufficiency Cohort (CRIC) Study.

Other NIH sponsored projects include: 1) assessing the relationship of sleep apnea induced hypertension to the higher prevalence of hypertension and hypertensive end organ damage; 2) evaluation of the association between salt sensitivity with

determinants (Na pump and arachidonic acid P-450 metabolites) of intracellular iron concentration in African-American and White female postmenopausal normotensives and hypertensives; and 3) the effect of caregiving on cardiovascular responses in African American female caregivers.